芪胶升白胶囊辅助放化疗治疗中晚期宫颈癌对TK1、Cyclin D1和ANG-2的影响

摘要/Abstract

摘要： 目的：观察芪胶升白胶囊辅助放化疗治疗中晚期宫颈癌的疗效，及其对胸苷激酶1（TK1）、血管生成素-2 （ANG-2）和细胞周期蛋白D1（Cyclin D1）的影响。方法：选择2016年1月至2018年12月在我院诊治的中晚期宫颈癌患者90例，按照随机数字方法将患者分为观察组和对照组，每组各45例。对照组予以放化疗，观察组在对照组的基础上予以芪胶升白胶囊辅助治疗。比较两组治疗后的疗效和并发症，以及两组治疗前后糖类抗原（CA）125、人附睾分泌蛋白-4（HE-4）、癌胚抗原（CEA）、CD4+、CD8+、NK、TK1、Cyclin D1和ANG-2水平的变化。结果：观察组的总有效率为75.56%，高于对照组的51.11%（χ2=4.785，P<0.05）。观察组的恶心呕吐和白细胞减少发生率低于对照组（P<0.05），而两组的血红蛋白减少和血小板减少发生率差异无统计学意义（P>0.05）。两组治疗前CA125、HE-4、CEA、CD4+、CD8+、NK、TK1、Cyclin D1和ANG-2水平差异无统计学意义（P>0.05），治疗后CA125、HE-4、CEA、TK1、Cyclin D1和ANG-2水平均较治疗前降低，且观察组降低水平较对照组更为明显（P<0.01）；治疗后观察组的CD4+和NK水平较治疗前和对照组均升高（P<0.01），而CD8+水平较治疗前和对照组均降低（P<0.01），对照组治疗前后的CD4+，CD8+和NK水平差异无统计学意义（P>0.05）。结论：芪胶升白胶囊辅助放化疗能够提高中晚期宫颈癌疗效，降低并发症，其可能的机制与降低机体TK1、Cyclin D1和ANG-2的水平相关。

关键词: font-size:medium, ">芪胶升白胶囊；中晚期宫颈癌；胸苷激酶1；血管生成素-2；细胞周期蛋白D1

Abstract: Objective： To observe the efficacy of qijiao shengbai capsule in adjuvant chemoradiotherapy for advanced cervical cancer and its impact on thymidine kinase 1 (TK1)， angiopoietin-2 (ANG-2)， and cyclin D1 (Cyclin D1). Methods： 90 patients with advanced cervical cancer diagnosed and treated in our hospital from January 2016 to December 2018 were divided into the observation group and the control group according to random number method， each group 45 cases. The control group was treated with chemoradiotherapy， and the observation group was treated with qijiao shengbai capsule on basis of the control group. The efficacy and complications after treatment were compared between the two groups， and the levels of carbohydrate antigen (CA) 125， human sapiens epididymis specific protein4 (HE-4)， carcinoembryonic antigen (CEA)， CD4+， CD8+， NK， TK1， Cyclin Changes in D1 and ANG-2 were compared between the two groups before and after treatment. Results： The total effective rate was 75.56% in the observation group， which was higher than 51.11% in the control group (χ2=4.785， P<0.05). The incidence of nausea， vomiting and leukopenia in the observation group was lower than that in the control group (P<0.05)， while the incidence of hemoglobin reduction and thrombocytopenia was not significantly different between the two groups (P>0.05). The levels of CA125， HE-4， CEA， CD4+， CD8+， NK， TK1， Cyclin D1， and ANG-2 were not significantly different between the two groups before treatment (P>0.05). After treatment， the levels of CA125， HE-4， CEA， TK1， Cyclin D1， and ANG-2 were lower than those before treatment (P<0.01)， and decrease levels in observation group were more obvious than those in the control group (P<0.01). The levels of CD4+ and NK in the observation group after treatment were higher than those before treatment and in the control group (P<0.01)， while the CD8+ level were lower than those before treatment and in the control group (P<0.01). There was no statistically significant difference of CD4+， CD8+ and NK in the control group between before and after treatment (P>0.05). Conclusion： Qijiao shengbai capsule in adjuvant chemoradiotherapy can improve the efficacy of cervical cancer in the middle and advanced stages cervical cancer and reduce complications， which mechanism may be related to lowering the levels of TK1， Cyclin D1 and ANG-2.

Key words: font-size:medium, ">Qijiao shengbai capsule； Advanced cervical cancer； Thymidine kinase 1； Angiopoietin-2； Cyclin D1

中图分类号:

黄艳冰. 芪胶升白胶囊辅助放化疗治疗中晚期宫颈癌对TK1、Cyclin D1和ANG-2的影响[J]. 中国医药导刊, 2021, 23(4): 256-260.

HUANG Yanbing. Impact of Qijiao Shengbai Capsule on TK1， Cyclin D1 and ANG-2 in the Adjuvant Chemoradiotherapy for Advanced Cervical Cancer[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(4): 256-260.

参考文献

[1]Buskwofie A， David-West G， Clare C A. A Review of cervical cancer： incidence and disparities[J]. J Natl Med Assoc，2020，112(2)：229-232.
     [2]曹泽毅主编.中华妇产科学[M]. 第2版.北京：人民卫生出版社，2008：2012-2028.
     [3]Lee HJ， Kim JM， Chin YJ， et al. Prognostic value of hematological parameters in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy[J]. Anticancer Res，2020，40(1)：451-458.
     [4]Meng Q， Liu X， Wang W， et al. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer， stage IIIB in the 2018 FIGO classification[J]. Radiat Oncol，2019，14(1)：228.
     [5]Li X， Zhou J， Chu C， et al. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy[J]. Head Neck，2019，41(10)：3525-3534.
     [6]于红，王维涛，嵇钧安，等. 芪胶升白胶囊联合粒细胞集落刺激因子治疗癌症化疗后骨髓抑制疗效观察[J]. 现代中西医结合杂志，2019，28(6)：621-623.
     [7]Li F， Wu Y， Kong W， et al. Clinical efficacy of preoperative vaginal intracavitary irradiation for Stage Ib2 and IIa cervical cancer[J]. J Cancer Res Ther，2017，13(5)：796-800.
     [8]宋振国，何振，苏永林，等. 芪胶升白胶囊对食管癌患者化疗后免疫状态及生活质量影响的研究[J]. 陕西中医，2018，39(6)：743-745.
     [9]侯晓杰，李玮，张建锋. 芪胶升白胶囊药理作用及临床研究进展[J]. 微量元素与健康研究，2018，35(1)：74-76.
     [10]赵书元，余辉，傅琪琳，等. 芪胶升白胶囊联合重组人粒细胞刺激因子治疗肝癌患者介入术后骨髓抑制疗效研究[J]. 陕西中医，2018，39(10)：1390-1392.
     [11]范圣涛，倪烨. 芪胶升白胶囊联合化疗对肿瘤患者白细胞减少的效果研究[J]. 深圳中西医结合杂志，2018，28(21)：28-29.
     [12]Chang C， Chen J， Chang WY， et al. Tumor size has a time-varying effect on recurrence in cervical cancer[J]. J Low Genit Tract Dis，2016，20(4)：317-320.
     [13]陈旻，林春华，唐蜜，等. SCC-Ag、CEA及HE4测定对宫颈癌的诊断价值研究[J]. 中国妇幼卫生杂志，2018，9(1)：40-43.
     [14]Jin Y， Kim SC， Kim HJ， et al. Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer[J]. Oncotarget，2017，8(62)：105425-105439.
     [15]Valenti G， Vitale SG， Tropea A， et al. Tumor markers of uterine cervical cancer： a new scenario to guide surgical practice?[J]. Updates Surg，2017，69(4)：441-449.
     [16]Malvi P， Janostiak R， Nagarajan A， et al. Loss of thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by reducing GDF15 expression[J]. PLoS Genet，2019，15(10)：e1008439.
     [17]Del RM， Bertolini I， Crucitta S， et al. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients[J]. Breast Cancer Res Treat，2019，178(1)：57-62.
     [18]Kunos CA， Ferris G， Pyatka N， et al. Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers[J]. Radiat Res，2011，176(4)：425-433.
     [19]Kim G J， Kim D H， Min K W， et al. Prognostic impact of high p16/cyclin D1 index in breast cancer[J]. Int J Clin Exp Pathol，2019，12(6)：2224-2232.
     [20]Luangdilok S， Wanchaijiraboon P， Chantranuwatana P， et al. Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer[J]. Transl Lung Cancer Res，2019，8(6)：959-966.
     [21]Coelho AL， Gomes MP， Catarino RJ， et al. CSF-1 and Ang-2 serum levels-prognostic and diagnostic partners in non-small cell lung cancer[J]. ESMO Open，2018，3(5)：e349.
     [22]蔡培培，祁永军，缪敏. 小牛脾提取物辅助化疗对中晚期胃癌患者肿瘤负荷和免疫功能的影响[J]. 临床与病理杂志，2019，39(6)：1203-1209.

快速检索引用检索图表检索高级检索